
Pharmakab Laboratories Private Limited
About Pharmakab Laboratories Private Limited
Data last updated:
Pharmakab Laboratories Private Limited was a private limited company based in Solapur, Maharashtra, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 03 February 2009.
The company was registered with the Registrar of Companies (ROC), Pune, under CIN U24232PN2009PTC133462.
The company had an authorised share capital of ₹2 Lakh and a paid-up capital of ₹80,000. It was led by directors Jemini Atul Bakshi and Atul Shantilal Bakshi.
Its last annual general meeting (AGM) was held on 10 May 2021, and its latest financial statements are for the year ended 31 March 2021. The registered office was at E – 7 – 8 M I D C Akkalkot Road, Solapur, Maharashtra, India – 413006.
As per the financials filed for FY 2019, the company reported a revenue of ₹13,000, a growth of 8% compared to the previous year. For the same year it recorded a net loss of ₹2.35 Lakh and EBITDA of -₹2.35 Lakh.
Company details
Contact details
Pharmakab Laboratories Private Limited's registered office is in Solapur, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressE – 7 – 8 M I D C Akkalkot Road, Solapur, Maharashtra, India – 413006
- IndustryHealthcare, Medical & Laboratory Equipment
To see the full contact details of Pharmakab Laboratories Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Pharmakab Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
Financials of Pharmakab Laboratories Private Limited
FY 2021 filings availablePharmakab Laboratories Private Limited reported revenue of ₹13,000 (up 8% YoY) for FY 2019.
Compounded Annual Growth Rate (CAGR)
Revenue rose 8% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹13,000 | ||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹2.35 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.35 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Pharmakab Laboratories Private Limited, buy the company report.
Board of directors of Pharmakab Laboratories Private Limited
Pharmakab Laboratories has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Jemini Atul Bakshi Also directs: Aditi Pharmaceuticals Pvt Ltd | Director | 31 Aug 2018 | 8 Years 2 Months | As last reported |
| Atul Shantilal Bakshi | Director | 03 Feb 2009 | 17 Years 8 Months | As last reported |
Shareholding
The shareholding of Pharmakab Laboratories Private Limited is on record for FY 2019, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2019 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Public | |
| Others |
To see the full shareholding pattern of Pharmakab Laboratories Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Pharmakab Laboratories Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Pharmakab Laboratories Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Pharmakab Laboratories Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Pharmakab Laboratories Private Limited has 4 board changes on record since 2009: 2 appointments and 2 cessations. The latest: Jemini Atul Bakshi ceased to be Additional Director on 17 May 2019.
Frequently asked questions
Pharmakab Laboratories has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Pharmakab Laboratories was a private limited company based in Solapur, Maharashtra, India. The company worked in medical and laboratory equipment, within the healthcare industry. It was incorporated on 03 February 2009 and is registered under CIN U24232PN2009PTC133462. The company has been struck off by the Registrar of Companies and is no longer operational.
Pharmakab Laboratories had 2 directors:
- Jemini Atul Bakshi - Director
- Atul Shantilal Bakshi - Director
The CIN (Corporate Identification Number) of Pharmakab Laboratories is U24232PN2009PTC133462. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Pharmakab Laboratories is at E – 7 – 8 M I D C Akkalkot Road, Solapur, Maharashtra, India – 413006.
Pharmakab Laboratories was incorporated on 03 February 2009. It is registered with the Registrar of Companies, Pune.
The latest financial statements of Pharmakab Laboratories on record with the MCA are for the year ended 31 March 2021. Its last annual general meeting was held on 10 May 2021. Year-wise statements from 2015 are in the company report.
Pharmakab Laboratories operated in the healthcare industry, in the medical and laboratory equipment segment. It worked in this industry before it was struck off.
Jemini Atul Bakshi ceased to be Additional Director on 17 May 2019. Manjula Shantilal Bakshi ceased to be Director on 13 Dec 2018. Jemini Atul Bakshi was appointed as Director on 31 Aug 2018. Pharmakab Laboratories has 4 board changes on record in total.
The compliance status of Pharmakab Laboratories is compliant as of 02 July 2026.

